How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000
Lei Chen, Sophie L Rogers, Stephen Colagiuri, Dominique A Cadilhac, Timothy H Mathew, Andrew N Boyden, Anna Peeters, Dianna J Magliano, Jonathan E Shaw, Paul Z Zimmet, Andrew M Tonkin
Medical Journal of Australia | WILEY | Published : 2008
The work described here was partly supported by a grant from the Commonwealth Department of Health and Aged Care. Lei Chen is supported by an Australian Postgraduate Award scholarship. We are grateful to the following for their support of the AusDiab study: the Commonwealth Department of Health and Aged Care, Abbott Australasia, Alpha-pharm, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Merck Lipha, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pharmacia and Upjohn, Pfizer, Roche Diagnostics, Sanofi Synthelabo, Servier, BioRad, HITECH Pathology, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services, and Health Department of Western Australia. For their invaluable contribution to AusDiab set-up and field activities, we are grateful to A Allman, B Atkins, S Bennett, S Chadban, S Colagiuri, M de Courten, M Dalton, M D'Embden, D Dunstan, T Dwyer, D Jolley, I Kemp, P Magnus, J Mathews, D McCarty, A Meehan, K O'Dea, P Phillips, P Popplewell, C Reid, A Stewart, R Tapp, H Taylor, T Welborn and F Wilson.